Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-384-8
CAS number: 25973-55-1
The test substance is a light yellow powder with a molecular
weight of 351.49 g/mol. The log P o/w value is 7.25 and the solubility
in water is < 1 µg/l (20°C, pH 6.3). The particle size was examined to
be < 10 µm = 37.9 % and < 4 µm = 7.2% (MMD = 11.5 µm).
In an acute oral toxicity study, TIF: RAIf (SPF) rats were
administered doses of up to 7750 mg/kg body weight per gavage
(CIBA-Geigy study, Siss 6481, 1978). No mortalities occurred and the
LD50 oral was set to be > 7750 mg/kg body weight. However, according to
the physico-chemical properties (molecular weight, log P o/w)
the test substance is expected to be absorbed through the
gastrointestinal tract (ECHA R7c). This is supported by two independent
subchronic studies conducted in beagle dogs (Inbifo, No. A 0176/049,
1970) and albino rats (TNO, No. R 2640, 1968). The test substance was
administered via the diet in doses of 15 - 240 mg/kg body weight and 10
- 173 mg/kg body weight, respectively. In both studies significant food
depression occurred and one dog starved. No further mortalities
occurred. Both studies report liver effects induced by the test
substance down to the lowest dose levels applied. Furthermore, effects
on kidneys and discolouration of the urine were observed, indicating a
systemic availability of the test substance. Based on the lipophilic
properties of the test substance, the liver appears to be the main site
of metabolism. The metabolites are assumed to be excreted predominantly
via the renal pathway.
The dermal uptake of the test substance is unlikely due to its
physico-chemical parameters. However, in a dermal repeated dose study
conducted in albino rabbits (University of Miami, No. 69, 1977) with 140
mg/kg body weight, discolouration of the urine was observed. Indicating
a systemic availability, it is not clear, whether the test substance was
absorbed via the dermal route or the uptake was artificial because of
inappropriate experimental design. Furthermore, the test substance did
not exhibit any acute dermal toxicity (Geigy (U. K.) Ltd., 8/69/S. L.,
1969), skin irritative / corrosive (CIBA-Geigy, No. 874135, 1987), eye
irritative (CIBA-Geigy, No. 874134, 1987) or skin sensitisation
properties (CIBA-Geigy, No. 874136, 1987), respectively.
Inhalative absorption of the test substance is likely due to the
particle size and the physico-chemical parameters (poor water solubility
and log P o/w). In contrast, an acute inhalative toxicity
study (CIBA-Geigy, Siss 3502, 1973) did not reveal signs for
bioavailability via the respiratory pathway. Tif. RAI rats were exposed
using a nose-only system to a technically maximal achievable analytical
substance concentration of 0.4 mg/l for 4 hours and did not show any
clinical sign of toxic effects of the test substance.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again